{"title":"脾边缘区淋巴瘤伴POD24的临床特点及预后分析。","authors":"L Wang, Q Shi, W L Zhao, L Wang","doi":"10.3760/cma.j.cn121090-20240729-00285","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the clinical characteristics, prognosis, and risk factors associated with disease progression within 24 months (POD24) after diagnosis in patients with splenic marginal zone lymphoma (SMZL) . <b>Methods:</b> Clinical data from 88 newly diagnosed SMZL patients treated at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, between December 2009 and October 2022, were retrospectively analyzed. Patients were grouped based on the presence of POD24 for prognostic evaluation and comparison of clinical features. <b>Results:</b> There were 45 males (51.1% ) and 43 females (48.9% ), with a median age of 59 (24-82) years at the time of diagnosis. Ten (11.4% ) cases occurred POD24. The overall survival (OS) time and progression- free survival (PFS) time in the POD24 group were shorten than non-POD24 group [median OS time: 77 (11-159) months <i>vs</i> not reached, <i>P</i><0.001; 15 (4-24) months <i>vs</i> 121 (24-154) months, <i>P</i><0.001]. Univariate Cox analysis showed that Eastern Cooperative Oncology Group (ECOG) score ≥ 2 [<i>HR</i>=8.942 (95% <i>CI</i> 1.097-72.910), <i>P</i>=0.041], age-adjusted International Prognostic Index (aaIPI) score of high-risk [<i>HR</i>=5.070 (95% <i>CI</i> 1.256-20.461), <i>P</i>=0.023], POD24 [<i>HR</i>=14.049 (95% <i>CI</i> 3.339-59.107), <i>P</i><0.001], occurrence of tissue transformation [<i>HR</i>=7.819 (95% <i>CI</i> 1.952-31.316), <i>P</i>=0.004], and disease unremission status after initial treatment [<i>HR</i>=6.080 (95% <i>CI</i> 1.439-25.690), <i>P</i>=0.014] were the influencing factors for OS in SMZL patients. Multivariate analysis showed that POD24 [<i>HR</i>=5.859 (95% <i>CI</i> 1.249-27.475), <i>P</i>=0.025] and occurrence of tissue transformation [<i>HR</i>=5.520 (95% <i>CI</i> 1.050-29.009), <i>P</i>=0.044] were independent prognostic factors affecting OS. Univariate logistic analysis showed that ECOG ≥ 2 [<i>HR</i>=7.556 (95% <i>CI</i> 1.498-38.110), <i>P</i>=0.014], high risk of aaIPI score [<i>HR</i>=5.500 (95% <i>CI</i> 1.378- 21.945), <i>P</i>=0.016], occurrence of tissue transformation [<i>HR</i>=8.000 (95% <i>CI</i> 1.759-36.383), <i>P</i>=0.007], and disease unremission status after initial treatment [<i>HR</i>=9.136 (95% <i>CI</i> 2.216-37.675), <i>P</i>=0.002] were the influencing factors of POD24. Multifactorial analysis showed that disease unremission after initial treatment [<i>HR</i>=8.253 (95% <i>CI</i> 1.681- 40.518), <i>P</i>=0.009] was an independent risk factor affecting POD24. <b>Conclusions:</b> POD24 and tissue transformation are independent poor prognostic factors for OS in SMZL patients. Patients with POD24 are at a higher risk of developing tissue transformation. The failure to alleviate the disease after initial treatment is an independent risk factor affecting POD24 patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"81-87"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886443/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Clinical features and prognosis of splenic marginal zone lymphoma with POD24].\",\"authors\":\"L Wang, Q Shi, W L Zhao, L Wang\",\"doi\":\"10.3760/cma.j.cn121090-20240729-00285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To investigate the clinical characteristics, prognosis, and risk factors associated with disease progression within 24 months (POD24) after diagnosis in patients with splenic marginal zone lymphoma (SMZL) . <b>Methods:</b> Clinical data from 88 newly diagnosed SMZL patients treated at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, between December 2009 and October 2022, were retrospectively analyzed. Patients were grouped based on the presence of POD24 for prognostic evaluation and comparison of clinical features. <b>Results:</b> There were 45 males (51.1% ) and 43 females (48.9% ), with a median age of 59 (24-82) years at the time of diagnosis. Ten (11.4% ) cases occurred POD24. The overall survival (OS) time and progression- free survival (PFS) time in the POD24 group were shorten than non-POD24 group [median OS time: 77 (11-159) months <i>vs</i> not reached, <i>P</i><0.001; 15 (4-24) months <i>vs</i> 121 (24-154) months, <i>P</i><0.001]. Univariate Cox analysis showed that Eastern Cooperative Oncology Group (ECOG) score ≥ 2 [<i>HR</i>=8.942 (95% <i>CI</i> 1.097-72.910), <i>P</i>=0.041], age-adjusted International Prognostic Index (aaIPI) score of high-risk [<i>HR</i>=5.070 (95% <i>CI</i> 1.256-20.461), <i>P</i>=0.023], POD24 [<i>HR</i>=14.049 (95% <i>CI</i> 3.339-59.107), <i>P</i><0.001], occurrence of tissue transformation [<i>HR</i>=7.819 (95% <i>CI</i> 1.952-31.316), <i>P</i>=0.004], and disease unremission status after initial treatment [<i>HR</i>=6.080 (95% <i>CI</i> 1.439-25.690), <i>P</i>=0.014] were the influencing factors for OS in SMZL patients. Multivariate analysis showed that POD24 [<i>HR</i>=5.859 (95% <i>CI</i> 1.249-27.475), <i>P</i>=0.025] and occurrence of tissue transformation [<i>HR</i>=5.520 (95% <i>CI</i> 1.050-29.009), <i>P</i>=0.044] were independent prognostic factors affecting OS. Univariate logistic analysis showed that ECOG ≥ 2 [<i>HR</i>=7.556 (95% <i>CI</i> 1.498-38.110), <i>P</i>=0.014], high risk of aaIPI score [<i>HR</i>=5.500 (95% <i>CI</i> 1.378- 21.945), <i>P</i>=0.016], occurrence of tissue transformation [<i>HR</i>=8.000 (95% <i>CI</i> 1.759-36.383), <i>P</i>=0.007], and disease unremission status after initial treatment [<i>HR</i>=9.136 (95% <i>CI</i> 2.216-37.675), <i>P</i>=0.002] were the influencing factors of POD24. Multifactorial analysis showed that disease unremission after initial treatment [<i>HR</i>=8.253 (95% <i>CI</i> 1.681- 40.518), <i>P</i>=0.009] was an independent risk factor affecting POD24. <b>Conclusions:</b> POD24 and tissue transformation are independent poor prognostic factors for OS in SMZL patients. Patients with POD24 are at a higher risk of developing tissue transformation. The failure to alleviate the disease after initial treatment is an independent risk factor affecting POD24 patients.</p>\",\"PeriodicalId\":24016,\"journal\":{\"name\":\"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\",\"volume\":\"46 1\",\"pages\":\"81-87\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886443/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn121090-20240729-00285\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn121090-20240729-00285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨脾边缘区淋巴瘤(SMZL)患者诊断后24个月内疾病进展的临床特点、预后及相关危险因素。方法:回顾性分析2009年12月至2022年10月上海交通大学医学院附属瑞金医院收治的88例新发SMZL患者的临床资料。根据患者是否存在POD24进行分组,进行预后评估和临床特征比较。结果:男性45例(51.1%),女性43例(48.9%),诊断时中位年龄59(24 ~ 82)岁。10例(11.4%)发生POD24。POD24组的总生存期(OS)时间和无进展生存期(PFS)时间均短于非POD24组[中位OS时间:77(11-159)个月vs未达到,pv vs 121(24-154)个月,PHR=8.942 (95% CI 1.097-72.910), P=0.041],年龄调整的国际预后指数(aaIPI)高危评分[HR=5.070 (95% CI 1.256-20.461), P=0.023], POD24 [HR=14.049 (95% CI 3.339-59.107), PHR=7.819 (95% CI 1.952-31.316), P=0.004],初始治疗后疾病未缓解状态[HR=6.080 (95% CI 1.439-25.690), P=0.014]是SMZL患者OS的影响因素。多因素分析显示,POD24 [HR=5.859 (95% CI 1.249 ~ 27.475), P=0.025]和组织转化的发生[HR=5.520 (95% CI 1.050 ~ 29.009), P=0.044]是影响OS的独立预后因素。单因素logistic分析显示,ECOG≥2 [HR=7.556 (95% CI 1.498 ~ 38.110), P=0.014]、aaIPI评分高危[HR=5.500 (95% CI 1.378 ~ 21.945), P=0.016]、组织转化发生[HR=8.000 (95% CI 1.759 ~ 36.383), P=0.007]、初始治疗后疾病未缓解状态[HR=9.136 (95% CI 2.216 ~ 37.675), P=0.002]是POD24的影响因素。多因素分析显示,初始治疗后疾病未缓解[HR=8.253 (95% CI 1.681 ~ 40.518), P=0.009]是影响POD24的独立危险因素。结论:POD24和组织转化是SMZL患者OS的独立不良预后因素。患有POD24的患者发生组织转化的风险更高。初始治疗后病情未能得到缓解是影响POD24患者的独立危险因素。
[Clinical features and prognosis of splenic marginal zone lymphoma with POD24].
Objective: To investigate the clinical characteristics, prognosis, and risk factors associated with disease progression within 24 months (POD24) after diagnosis in patients with splenic marginal zone lymphoma (SMZL) . Methods: Clinical data from 88 newly diagnosed SMZL patients treated at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, between December 2009 and October 2022, were retrospectively analyzed. Patients were grouped based on the presence of POD24 for prognostic evaluation and comparison of clinical features. Results: There were 45 males (51.1% ) and 43 females (48.9% ), with a median age of 59 (24-82) years at the time of diagnosis. Ten (11.4% ) cases occurred POD24. The overall survival (OS) time and progression- free survival (PFS) time in the POD24 group were shorten than non-POD24 group [median OS time: 77 (11-159) months vs not reached, P<0.001; 15 (4-24) months vs 121 (24-154) months, P<0.001]. Univariate Cox analysis showed that Eastern Cooperative Oncology Group (ECOG) score ≥ 2 [HR=8.942 (95% CI 1.097-72.910), P=0.041], age-adjusted International Prognostic Index (aaIPI) score of high-risk [HR=5.070 (95% CI 1.256-20.461), P=0.023], POD24 [HR=14.049 (95% CI 3.339-59.107), P<0.001], occurrence of tissue transformation [HR=7.819 (95% CI 1.952-31.316), P=0.004], and disease unremission status after initial treatment [HR=6.080 (95% CI 1.439-25.690), P=0.014] were the influencing factors for OS in SMZL patients. Multivariate analysis showed that POD24 [HR=5.859 (95% CI 1.249-27.475), P=0.025] and occurrence of tissue transformation [HR=5.520 (95% CI 1.050-29.009), P=0.044] were independent prognostic factors affecting OS. Univariate logistic analysis showed that ECOG ≥ 2 [HR=7.556 (95% CI 1.498-38.110), P=0.014], high risk of aaIPI score [HR=5.500 (95% CI 1.378- 21.945), P=0.016], occurrence of tissue transformation [HR=8.000 (95% CI 1.759-36.383), P=0.007], and disease unremission status after initial treatment [HR=9.136 (95% CI 2.216-37.675), P=0.002] were the influencing factors of POD24. Multifactorial analysis showed that disease unremission after initial treatment [HR=8.253 (95% CI 1.681- 40.518), P=0.009] was an independent risk factor affecting POD24. Conclusions: POD24 and tissue transformation are independent poor prognostic factors for OS in SMZL patients. Patients with POD24 are at a higher risk of developing tissue transformation. The failure to alleviate the disease after initial treatment is an independent risk factor affecting POD24 patients.